14th International Congress on Autoimmunity 2024
Sebia booth #15
The next generation instrument for screening hemoglobin disorders in newborns.
European Myeloma Network Meeting – EMN 2024
Sebia booth: #9
Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.
Educational Workshop with Dr. Barbara De la Salle
Learn more about the HYDRASYS 2 SCAN FOCUSING for a fast and user-friendly gel electrophoresis processing.
Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma
Sebia Academy Webinar con la Dott.ssa Maria Paola Simula, laurea in Scienze biologiche, specializzazione in Biochimica Clinica nel 2002